Althea Technologies has been awarded a contract from Altus Pharmaceuticals to produce its ALTU-238 product candidate, a crystallized formulation of Human Growth Hormone (HGH) that is designed to be administered once-weekly through a fine gauge needle for the treatment of HGH disorders.

“Althea Technologies is a seasoned CMO with significant experience in the manufacture of recombinant proteins,” said Sheldon Berkle, president and chief executive officer of Altus. “We look forward to working together through technology transfer and the installation and qualification of the key equipment necessary for the production of ALTU-238. We feel confident in their ability to manufacture reliable quantities of ALTU-238 for our planned Phase III trials that meet our high standards of quality and patient safety.”

Althea Technologies will manufacture the Phase III trial material of ALTU-238 human growth hormone in its newly expanded cGMP manufacturing facilities at its San Diego, CA campus. President and co-chief executive officer of Althea, Dr. Magda Marquet, added, “We are pleased that Altus Pharmaceuticals selected Althea Technologies to manufacture their innovative ALTU-238 product. As a leader in providing highly technical drug development services to the industry, we are committed to working with Altus to effectively and efficiently manufacture ALTU-238.”